Point-of-Care Glucose Testing Global Market Report 2024

The point-of-care glucose testing market size has grown strongly in recent years. It will grow from $4.63 billion in 2023 to $4.88 billion in 2024 at a compound annual growth rate (CAGR) of 5.4%. The growth observed in the historical period can be credited to the increasing prevalence of diabetes, heightened awareness of diabetes management, the expansion of the aging population, the augmentation of healthcare infrastructure, and the adoption of point-of-care testing.

The point-of-care glucose testing market size is expected to see strong growth in the next few years. It will grow to $5.99 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The anticipated growth in the forecast period can be ascribed to the expansion of telemedicine services, an increasing emphasis on personalized medicine in diabetes care, the proliferation of diabetes management programs, heightened investment in research and development related to glucose testing, and the adoption of continuous glucose monitoring. Key trends expected in the forecast period encompass the development of wearable glucose monitoring devices, the integration of smartphone connectivity in glucose testing, the proliferation of point-of-care testing in home healthcare settings, the adoption of artificial intelligence in glucose data analysis, and the expansion of remote patient monitoring for diabetes.

The point-of-care glucose testing market is anticipated to experience growth, driven by the increasing prevalence of diabetes. Diabetes, a chronic metabolic disorder elevating blood glucose levels, poses severe risks to various organs over time. Point-of-care glucose testing, a widely used technology, aids in determining glucose levels in hospitalized patients, facilitating prompt treatment decisions in response to glycemic changes. Notably, this technology enhances therapeutic outcomes and improves diabetes management. Statistics from 2022 by the Centers for Disease Control and Prevention (CDC) revealed that around 37.3 million people had diabetes in the United States in 2021, constituting 11.3% of the population. Additionally, projections from the International Diabetes Federation in November 2021 forecasted a global diabetic population increase from 643 million (11.3%) in 2030 to 783 million (12.2%) by 2045, underscoring the significant impact of diabetes on the point-of-care glucose testing market.

The growth of the point-of-care glucose testing market is further fueled by the rising aging population. As demographics shift toward an aging population, characterized by an increasing proportion of elderly individuals, point-of-care glucose testing becomes increasingly crucial. This technology serves essential purposes for older individuals, particularly those at higher risk of diabetes or already diagnosed. The World Health Organization projected that by 2030, one out of every six individuals globally would be 60 years old or older. The proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion, and by 2050, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion. Therefore, the growing aging population is a significant driver of the point-of-care glucose testing market.

Product innovation is a key trend gaining traction in the point-of-care glucose testing market, with major companies focused on developing innovative products. For instance, F. Hoffmann-La Roche AG introduced Cobas Pulse in January 2022, a new point-of-care blood glucose monitor designed for healthcare staff. This handheld device includes an automated glucose test strip reader, camera, and touchscreen, housed in a rugged casing that can be disinfected and used across all age groups, including newborns and intensive care patients. The innovation aims to enhance physicians' workflow by integrating Glucommander dosage software and offering downloadable decision-support apps.

Major companies in the point-of-care glucose testing market are also directing their efforts towards developing advanced solutions such as glucose-ketone monitoring sensors. Abbott Laboratories announced in June 2022 the development of a first-of-its-kind biowearable sensor system that continuously monitors glucose and ketones in diabetic patients. This breakthrough device, granted FDA designation, represents a significant advancement in regulatory status and is set to become the most compact and slender monitoring device globally. It integrates seamlessly with Abbott's digital ecosystem, allowing remote monitoring by healthcare professionals.

In November 2021, Johnson & Johnson acquired Inverness Medical Technology for $1.3 billion, aiming to strengthen its product portfolio in glucose testing. Inverness Medical Technology, a medical device company, brought valuable resources and a robust pipeline of blood glucose meters and test strips to enhance Johnson & Johnson's competitive position in the point-of-care glucose testing market.

Major companies operating in the point-of-care glucose testing market report are F Hoffmann-La Roche Ltd., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, TaiDoc Technology Corporation, B. Braun Melsungen AG, Beckman Coulter Inc., Nipro Corporation, Dexcom Inc., Bio-Rad Laboratories Inc., LifeScan Inc., Nova Biomedical Corporation, Ypsomed AG, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Radiometer Medical ApS, HemoCue AB, EKF Diagnostics Holdings PLC, Trinity Biotech PLC, Bionime Corporation, PTS Diagnostics, ForaCare Inc., Menarini Diagnostics, ACON Laboratories Inc., Senseonics Holdings Inc., Prodigy Diabetes Care LLC, Nemaura Medical Inc., Bluedrop Medical Limited.

North America was the largest region in the point of care glucose testing market in 2023. The regions covered in the point-of-care glucose testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care glucose testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary components in point-of-care glucose testing encompass lancet and lancing devices, strips, and meters. Lancets, small sharp instruments, puncture the skin to extract a small blood drop for testing, while lancing devices securely hold the lancet and are activated with a simple button push. These devices facilitate straightforward blood withdrawal and assessment of blood glucose levels using a blood glucose monitor and test strips in point-of-care glucose testing. Testing sites include fingertips and alternate site testing, applied in both type-1 and type-2 diabetes. Various end-users, such as professional diagnostic centers, hospitals and clinics, home care settings, among others, utilize these methods.

The point-of-care glucose testing market research report is one of a series of new reports that provides point-of-care glucose testing market statistics, including point-of-care glucose testing industry global market size, regional shares, competitors with a point-of-care glucose testing market share, detailed point-of-care glucose testing market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care glucose testing industry. This point-of-care glucose testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The point-of-care glucose testing market consists of revenues earned by entities by providing services such as diagnosis, monitoring, screening, and testing regimes to offer enhanced therapeutic intervention and patient care in lesser time. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care glucose testing market also includes sales of rapid assay dipsticks, glucose monitoring kits, and multifunctional benchtop devices which are used in providing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.